Novavax and Takeda finalized license agreement for Novavax COVID-19 vaccine candidate in Japan
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
On Feb. 26, 2021, Johnson & Johnson announced that the FDA Vaccines and Related Biological Products Advisory Committee…
On Feb. 26, 2021, Regeneron announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
On Feb. 25, 2021, the U.S. Food and Drug Administration announced that it was allowing undiluted frozen vials…
On Feb. 25, 2021, Altimmune announced that it had commenced enrollment in a Phase 1 clinical trial of…
On Feb. 25, 2021, Chimerix reported topline results from the first cohort of its randomized, double-blind, placebo-controlled Phase…
On Feb. 25, 2021, Pfizer and BioNTech announced they had begun an evaluation of the safety and immunogenicity…
On Feb. 25, 2021, Regeneron announced changes to the phase 3 trial assessing investigational REGEN-COVï¾™ (casirivimab with imdevimab)…
On Feb. 24, 2021, scientists at the University of Oxford reported that overall deaths did not increase in…
On Feb. 24, 2021, Ghana became the first country outside India to receive COVID-19 vaccine doses shipped via…
On Feb. 24, 2021, XPhyto announced that it has placed the first order for its rapid point-of-care SARS-CoV-2…
On Feb. 24, 2021, NeuroRx, announced that the phase 2b/3 trial of ZYESAMI for the treatment of Respiratory…
On Feb. 24, 2021, Quest Diagnostics introduced a new COVID-19 testing service that aids in providing insight into…
On Feb. 23, 2021, Cue Health announced that its molecular point-of-care COVID-19 Test had received the CE mark,…
On Feb. 23, 2021, PerkinElmer announced the launch of the PerkinElmerï¾® COVID-19 Antigen Test for the qualitative detection…
On Feb. 22, 2021, Amyris announced highly promising preliminary data in a pre-clinical study of its ribonucleic acid…
On Feb. 22, 2021, Biohaven Pharmaceutical announced that a hyperimmune globulin mimic (HGM) developed with Biohaven’s proprietary MATE…
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
On Feb. 19, 2021, the ACT Accelerator partnership welcomed over US$ 4.3 billion of new investments from the…
On Feb. 19, 2021, Johnson & Johnson announced that Janssen-Cilag had submitted for Emergency Use Listing (EUL) to…
On Feb. 19, 2021, BioNTech announced the submission of new data to the FDA demonstrating the stability of…
On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…
On Feb. 18, 2021, scientists at the University of Oxford announced that the Randomised Evaluation of COVID-19 Therapy…
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
On Feb. 18, 2021, Washington University pediatric infectious diseases doctors announced plans to launch clinical trials in the…
On Feb. 18, 2021, Pfizer and BioNTech announced that the first participants hadbeen dosed in a global Phase…
On Feb. 17, 2021, the NIH annunced funding of a study to evaluate the effects of remdesivir in…
On Feb. 17, 2021, Moderna announced that the European Commission had purchased an additional 150 million doses of…
On Feb. 17, 2021, Altimmune announced that the FDA had cleared the Companyï¾’s Investigational New Drug (IND) application…
On Feb. 17, 2021, LabCorp announced the availability of a new laboratory-based antigen test that will help doctors…